<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>A3342</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Albertus Extra Bold";
	panose-1:2 14 8 2 4 3 4 2 2 4;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 6 4 5 2 3 4;}
@font-face
	{font-family:Albertus;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	background:navy;
	font-size:12.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:9.0pt;
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
p.FronterPage, li.FronterPage, div.FronterPage
	{mso-style-name:FronterPage;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Para10pt
	{mso-style-name:Para10pt;
	font-family:"Times New Roman",serif;}
p.PrefileFronterTitle, li.PrefileFronterTitle, div.PrefileFronterTitle
	{mso-style-name:PrefileFronterTitle;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:17.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.StylePrefileFronterTitleLeft, li.StylePrefileFronterTitleLeft, div.StylePrefileFronterTitleLeft
	{mso-style-name:"Style PrefileFronterTitle + Left";
	margin-top:0in;
	margin-right:-.2in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:17.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BillHead
	{mso-style-name:BillHead;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillHeading2
	{mso-style-name:BillHeading2;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillLanguage
	{mso-style-name:BillLanguage;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.HangingAnAct, li.HangingAnAct, div.HangingAnAct
	{mso-style-name:HangingAnAct;
	mso-style-link:"HangingAnAct Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.HangingAnActChar
	{mso-style-name:"HangingAnAct Char";
	mso-style-link:HangingAnAct;
	letter-spacing:.2pt;}
span.11ptChar
	{mso-style-name:11ptChar;
	font-family:"Times New Roman",serif;}
span.BillHeadUnBold
	{mso-style-name:BillHeadUnBold;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.bpuBill, li.bpuBill, div.bpuBill
	{mso-style-name:bpuBill;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:26.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuHeadSpon, li.bpuHeadSpon, div.bpuHeadSpon
	{mso-style-name:bpuHeadSpon;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.bpuHeadSponChar
	{mso-style-name:bpuHeadSponChar;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuIntro, li.bpuIntro, div.bpuIntro
	{mso-style-name:bpuIntro;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuLegislature, li.bpuLegislature, div.bpuLegislature
	{mso-style-name:bpuLegislature;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:24.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuNormText, li.bpuNormText, div.bpuNormText
	{mso-style-name:bpuNormText;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuReprint, li.bpuReprint, div.bpuReprint
	{mso-style-name:bpuReprint;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:22.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.bpuSponsor, li.bpuSponsor, div.bpuSponsor
	{mso-style-name:bpuSponsor;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuState, li.bpuState, div.bpuState
	{mso-style-name:bpuState;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:32.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.charMarlett
	{mso-style-name:charMarlett;
	font-family:Marlett;}
p.ElevenPt, li.ElevenPt, div.ElevenPt
	{mso-style-name:ElevenPt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPage12pt, li.FronterPage12pt, div.FronterPage12pt
	{mso-style-name:FronterPage12pt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageBillHeading, li.FronterPageBillHeading, div.FronterPageBillHeading
	{mso-style-name:FronterPageBillHeading;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.FronterPageNOCAPS, li.FronterPageNOCAPS, div.FronterPageNOCAPS
	{mso-style-name:FronterPageNOCAPS;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times",serif;}
p.FronterPageTBox2, li.FronterPageTBox2, div.FronterPageTBox2
	{mso-style-name:FronterPageTBox2;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageTextBox, li.FronterPageTextBox, div.FronterPageTextBox
	{mso-style-name:FronterPageTextBox;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.FronterSameAs, li.FronterSameAs, div.FronterSameAs
	{mso-style-name:FronterSameAs;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Pg2Footer, li.Pg2Footer, div.Pg2Footer
	{mso-style-name:Pg2Footer;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Style10pt
	{mso-style-name:"Style 10 pt";
	font-family:"Times New Roman",serif;}
p.StyleFronterPage11pt, li.StyleFronterPage11pt, div.StyleFronterPage11pt
	{mso-style-name:"Style FronterPage + 11 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.StyleFronterPageLoweredby3pt, li.StyleFronterPageLoweredby3pt, div.StyleFronterPageLoweredby3pt
	{mso-style-name:"Style FronterPage + Lowered by  3 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	position:relative;
	top:3.0pt;}
p.StyleFronterSameAsPatternSolid100White, li.StyleFronterSameAsPatternSolid100White, div.StyleFronterSameAsPatternSolid100White
	{mso-style-name:"Style FronterSameAs + Pattern\: Solid \(100%\) \(White\)";
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Style1, li.Style1, div.Style1
	{mso-style-name:Style1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Whereas
	{mso-style-name:Whereas;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
p.bpuWpGraphic, li.bpuWpGraphic, div.bpuWpGraphic
	{mso-style-name:bpuWpGraphic;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.LeftBrackt
	{mso-style-name:LeftBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.RightBrackt
	{mso-style-name:RightBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.Superscript
	{mso-style-name:Superscript;
	font-family:"Albertus",sans-serif;
	font-weight:bold;
	vertical-align:super;}
p.sponUdate, li.sponUdate, div.sponUdate
	{mso-style-name:sponUdate;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.BoldItal
	{mso-style-name:BoldItal;
	font-weight:bold;
	font-style:italic;}
p.amendfooter, li.amendfooter, div.amendfooter
	{mso-style-name:amendfooter;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.HangingSup, li.HangingSup, div.HangingSup
	{mso-style-name:HangingSup;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableBottom, li.HangingTableBottom, div.HangingTableBottom
	{mso-style-name:HangingTableBottom;
	margin-top:0in;
	margin-right:1.0in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableTop, li.HangingTableTop, div.HangingTableTop
	{mso-style-name:HangingTableTop;
	margin-top:0in;
	margin-right:.5in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:8.5in 14.0in;
	margin:1.5in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:8.5in 14.0in;
	margin:1.5in 113.75pt 1.0in 113.75pt;}
div.WordSection2
	{page:WordSection2;}
@page WordSection3
	{size:8.5in 14.0in;
	margin:1.0in 1.75in 1.2in 2.0in;}
div.WordSection3
	{page:WordSection3;}
-->
</style>

</head>

<body lang=EN-US>

<div class=WordSection1>

<p class=bpuBill><a name=bpuFrontPg></a>ASSEMBLY, No. 3342 </p>

<p class=bpuWpGraphic></p>

<p class=bpuState>STATE OF NEW JERSEY</p>

<p class=bpuLegislature>221st LEGISLATURE</p>

<p class=bpuWpGraphic>  </p>

<p class=bpuIntro>PRE-FILED FOR INTRODUCTION IN THE 2024 SESSION</p>

<p class=bpuIntro>&nbsp;</p>

</div>

<span style='font-size:12.0pt;line-height:120%;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:auto'>
</span>

<div class=WordSection2>

<p class=bpuIntro>&nbsp;</p>

<p class=bpuSponsor>Sponsored by:</p>

<p class=bpuSponsor>Assemblyman  PAUL KANITRA</p>

<p class=bpuSponsor>District 10 (Monmouth and Ocean)</p>

<p class=bpuSponsor>Assemblyman  GREGORY P. MCGUCKIN</p>

<p class=bpuSponsor>District 10 (Monmouth and Ocean)</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>SYNOPSIS</p>

<p class=bpuNormText>     Requires health care practitioners prescribing opioid
medications to limit amount of prescribed medication to seven-day supply,
except in certain circumstances.</p>

<p class=bpuNormText> </p>

<p class=bpuSponsor>CURRENT VERSION OF TEXT </p>

<p class=bpuNormText>     As introduced.</p>

<p class=bpuNormText>   </p>

</div>

<span style='font-size:10.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection3>

<p class=HangingAnAct style='line-height:150%'><span class=BillHead>An Act</span><span
class=HangingAnActChar> concerning</span> prescriptions for opioid medications,
amending P.L.1997, c.249, and supplementing Title 24 of the Revised Statutes.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     <span class=BillHeading2>Be It
Enacted </span><span class=BillLanguage>by the Senate and General Assembly of
the State of New Jersey:</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     1. Section 11 of P.L.2017,
c.28 (C.24:21-15.2) is amended to read as follows:</p>

<p class=MsoNormal style='line-height:150%'>     11. a. A practitioner shall
not issue <b><span style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>an
initial<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b>
<u>a</u> prescription for an opioid drug which is a prescription drug as
defined in section 2 of P.L.2003, c.280 (C.45:14-41) in a quantity exceeding a <b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>five-day<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>seven-day</u>
supply for treatment of acute pain.  Any prescription for acute pain pursuant
to this subsection shall be for the lowest effective dose of immediate-release
opioid drug.  </p>

<p class=MsoNormal style='line-height:150%'>     b.    Prior to issuing an
initial prescription of a Schedule II controlled dangerous substance or any
other opioid drug which is a prescription drug as defined in section 2 of
P.L.2003, c.280 (C.45:14-41) in a course of treatment for acute or chronic
pain, a practitioner shall:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   take and document the
results of a thorough medical history, including the patient's experience with
non-opioid medication and non-pharmacological pain management approaches and
substance abuse history;</p>

<p class=MsoNormal style='line-height:150%'>     (2)   conduct, as appropriate,
and document the results of a physical examination;</p>

<p class=MsoNormal style='line-height:150%'>     (3)   develop a treatment
plan, with particular attention focused on determining the cause of the
patient's pain;</p>

<p class=MsoNormal style='line-height:150%'>     (4)   access relevant
prescription monitoring information under the Prescription Monitoring Program pursuant
to section 8 of P.L.2015, c.74 (C. 45:1-46.1); and</p>

<p class=MsoNormal style='line-height:150%'>     (5)   limit the supply of any
opioid drug prescribed for acute pain to a duration of no more than <b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>five<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>seven</u>
days as determined by the directed dosage and frequency of dosage.</p>

<p class=MsoNormal style='line-height:150%'>     c.     No less than <b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>four<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>six</u>
days after issuing <b><span style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>the
initial<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b>
<u>a</u> prescription pursuant to subsection a. of this subsection, the
practitioner, after consultation with the patient, may issue a subsequent
prescription for the drug to the patient <b><span style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>in
any quantity that complies with applicable State and federal laws<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>] </span></b><u>in a
quantity not exceeding a seven-day supply</u>, provided that:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   <b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>the subsequent
prescription would not be deemed an initial prescription under this section<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b>     <u>(Deleted
by amendment, P.L.   , c.    ) (pending before the Legislature as this bill)</u><b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>;<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b></p>

<p class=MsoNormal style='line-height:150%'>     (2)    the practitioner
determines the prescription is necessary and appropriate to the patient's
treatment needs and documents the rationale for the issuance of the subsequent
prescription; and</p>

<p class=MsoNormal style='line-height:150%'>     (3)    the practitioner determines
that issuance of the subsequent prescription does not present an undue risk of
abuse, addiction, or diversion and documents that determination.</p>

<p class=MsoNormal style='line-height:150%'>     d.    Prior to issuing <b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>the initial<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>a</u>
prescription of a Schedule II controlled dangerous substance or any other
opioid drug which is a prescription drug as defined in section 2 of P.L.2003,
c.280 (C.45:14-41) in a course of treatment for acute pain and prior to issuing
a prescription at the outset of a course of treatment for chronic pain, a
practitioner shall discuss with the patient, or the patient's parent or
guardian if the patient is under 18 years of age and is not an emancipated
minor, the risks associated with the drugs being prescribed, including but not
limited to: </p>

<p class=MsoNormal style='line-height:150%'>     (1)    the risks of addiction
and overdose associated with opioid drugs and the dangers of taking opioid
drugs with alcohol, benzodiazepines and other central nervous system
depressants;</p>

<p class=MsoNormal style='line-height:150%'>     (2)    the reasons why the
prescription is necessary; </p>

<p class=MsoNormal style='line-height:150%'>     (3)    alternative treatments
that may be available; and</p>

<p class=MsoNormal style='line-height:150%'>     (4)    risks associated with
the use of the drugs being prescribed, specifically that opioids are highly
addictive, even when taken as prescribed, that there is a risk of developing a
physical or psychological dependence on the controlled dangerous substance, and
that the risks of taking more opioids than prescribed, or mixing sedatives,
benzodiazepines or alcohol with opioids, can result in fatal respiratory
depression. </p>

<p class=MsoNormal style='line-height:150%'>     The practitioner shall include
a note in the patient's medical record that the patient or the patient's parent
or guardian, as applicable, has discussed with the practitioner the risks of
developing a physical or psychological dependence on the controlled dangerous substance
and alternative treatments that may be available.  The Division of Consumer
Affairs shall develop and make available to practitioners guidelines for the
discussion required pursuant to this subsection.</p>

<p class=MsoNormal style='line-height:150%'>     e.     Prior to the
commencement of an ongoing course of treatment for chronic pain with a Schedule
II controlled dangerous substance or any opioid, the practitioner shall enter
into a pain management agreement with the patient.</p>

<p class=MsoNormal style='line-height:150%'>     f.     When a Schedule II
controlled dangerous substance or any other prescription opioid drug is
continuously prescribed for three months or more for chronic pain, the
practitioner shall:</p>

<p class=MsoNormal style='line-height:150%'>     (1)    review, at a minimum of
every three months, the course of treatment, any new information about the
etiology of the pain, and the patient's progress toward treatment objectives
and document the results of that review;</p>

<p class=MsoNormal style='line-height:150%'>     (2)    assess the patient
prior to every renewal to determine whether the patient is experiencing
problems associated with physical and psychological dependence and document the
results of that assessment;</p>

<p class=MsoNormal style='line-height:150%'>     (3)    periodically make
reasonable efforts, unless clinically contraindicated, to either stop the use
of the controlled substance, decrease the dosage, try other drugs or treatment
modalities in an effort to reduce the potential for abuse or the development of
physical or psychological dependence and document with specificity the efforts
undertaken;</p>

<p class=MsoNormal style='line-height:150%'>     (4)    review the Prescription
Drug Monitoring information in accordance with section 8 of P.L.2015, c.74 (C.
45:1-46.1); and</p>

<p class=MsoNormal style='line-height:150%'>     (5)    monitor compliance with
the pain management agreement and any recommendations that the patient seek a
referral.</p>

<p class=MsoNormal style='line-height:150%'>     g.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     &quot;Acute pain&quot; means
pain, whether resulting from disease, accidental or intentional trauma, or
other cause, that the practitioner reasonably expects to last only a short
period of time.  &quot;Acute pain&quot; does not include chronic pain, pain
being treated as part of cancer care, hospice or other end of life care, or
pain being treated as part of palliative care.</p>

<p class=MsoNormal style='line-height:150%'>     &quot;Chronic pain&quot; means
pain that persists or recurs for more than three months.  </p>

<p class=MsoNormal style='line-height:150%'>     <b><span style='font-family:
"Albertus Extra Bold",sans-serif'>[</span></b>&quot;Initial prescription&quot;
means a prescription issued to a patient who:</p>

<p class=MsoNormal style='line-height:150%'>     (1)    has never previously
been issued a prescription for the drug or its pharmaceutical equivalent; or</p>

<p class=MsoNormal style='line-height:150%'>     (2)    was previously issued a
prescription for, or used or was administered the drug or its pharmaceutical
equivalent, but the date on which the current prescription is being issued is
more than one year after the date the patient last used or was administered the
drug or its equivalent.</p>

<p class=MsoNormal style='line-height:150%'>     When determining whether a
patient was previously issued a prescription for, or used or was administered a
drug or its pharmaceutical equivalent, the practitioner shall consult with the
patient and review the patient's medical record and prescription monitoring
information.<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b></p>

<p class=MsoNormal style='line-height:150%'>     &quot;Opioid antidote&quot;
means any drug, regardless of dosage amount or method of administration, which
has been approved by the United States Food and Drug Administration (FDA) for
the treatment of an opioid overdose.  &quot;Opioid antidote&quot; includes, but
is not limited to, naloxone hydrochloride, in any dosage amount, which is
administered through nasal spray or any other FDA-approved means or methods.</p>

<p class=MsoNormal style='line-height:150%'>     &quot;Pain management
agreement&quot; means a written contract or agreement that is executed between
a practitioner and a patient, prior to the commencement of treatment for
chronic pain using a Schedule II controlled dangerous substance or any other
opioid drug which is a prescription drug as defined in section 2 of P.L.2003,
c.280 (C.45:14-41), as a means to:</p>

<p class=MsoNormal style='line-height:150%'>     (1)    prevent the possible
development of physical or psychological dependence in the patient;</p>

<p class=MsoNormal style='line-height:150%'>     (2)    document the
understanding of both the practitioner and the patient regarding the patient's
pain management plan;</p>

<p class=MsoNormal style='line-height:150%'>     (3)    establish the patient's
rights in association with treatment, and the patient's obligations in relation
to the responsible use, discontinuation of use, and storage of Schedule II
controlled dangerous substances, including any restrictions on the refill of
prescriptions or the acceptance of Schedule II prescriptions from
practitioners;</p>

<p class=MsoNormal style='line-height:150%'>     (4)    identify the specific
medications and other modes of treatment, including physical therapy or
exercise, relaxation, or psychological counseling, that are included as a part
of the pain management plan;</p>

<p class=MsoNormal style='line-height:150%'>     (5)    specify the measures
the practitioner may employ to monitor the patient's compliance, including but
not limited to random specimen screens and pill counts; and</p>

<p class=MsoNormal style='line-height:150%'>     (6)    delineate the process
for terminating the agreement, including the consequences if the practitioner
has reason to believe that the patient is not complying with the terms of the
agreement.</p>

<p class=MsoNormal style='line-height:150%'>     &quot;Practitioner&quot; means
a medical doctor, doctor of osteopathy, dentist, optometrist, podiatrist,
physician assistant, certified nurse midwife, or advanced practice nurse,
acting within the scope of practice of their professional license pursuant to
Title 45 of the Revised Statutes.</p>

<p class=MsoNormal style='line-height:150%'>     h.    <u>(1)</u> This section
shall not apply to a prescription for a patient who is currently in active
treatment for cancer, receiving hospice care from a licensed hospice or
palliative care, or is a resident of a long term care facility, or to any
medications that are being prescribed for use in the treatment of substance
abuse or opioid dependence.</p>

<p class=MsoNormal style='line-height:150%'>     <u>(2) Notwithstanding any
provision of this section to the contrary, if a practitioner determines, in the
practitioners professional medical judgment, that the prescription of more
than a seven-day supply of opioid medication is necessary to treat a patients
acute medical condition, or is necessary to provide the patient with adequate
management of chronic pain, the practitioner may issue a prescription of more
than a seven-day supply of opioid medication.  The quantity of opioid
medication prescribed under this subsection shall not exceed the amounts
specified in section 1 of P.L.1997, c.249 (C.45:9-22.19), and shall be
consistent with any other applicable State and federal prescribing
requirements.  The condition triggering the prescription of more than a
seven-day supply of opioid medication shall be documented in the patients medical
record, and the practitioner shall also indicate therein that a non-opioid
alternative was not appropriate to treat the medical condition</u>.</p>

<p class=MsoNormal style='line-height:150%'>     i.     Every policy, contract
or plan delivered, issued, executed or renewed in this State, or approved for
issuance or renewal in this State by the Commissioner of Banking and Insurance,
and every contract purchased by the School Employees' Health Benefits
Commission or State Health Benefits Commission, on or after the effective date
of this act, that provides coverage for prescription drugs subject to a
co-payment, coinsurance or deductible shall charge a co-payment, coinsurance or
deductible for an initial prescription of an opioid drug prescribed pursuant to
this section that is either: </p>

<p class=MsoNormal style='line-height:150%'>     (1)   proportional between the
cost sharing for a 30-day supply and the amount of drugs the patient was
prescribed; or </p>

<p class=MsoNormal style='line-height:150%'>     (2)   equivalent to the cost
sharing for a full 30-day supply of the opioid drug, provided that no
additional cost sharing may be charged for any additional prescriptions for the
remainder of the 30-day supply.</p>

<p class=MsoNormal style='line-height:150%'>     j. (1) Subject to paragraph
(2) of this subsection, if a health care practitioner issues a prescription for
an opioid drug which is a controlled dangerous substance to a patient, the
prescriber shall additionally issue the patient a prescription for an opioid
antidote if any of the following conditions is present:</p>

<p class=MsoNormal style='line-height:150%'>     (a)   the patient has a
history of substance use disorder;</p>

<p class=MsoNormal style='line-height:150%'>     (b)   the prescription for the
opioid drug is for a daily dose of more than 90 morphine milligram equivalents;
or</p>

<p class=MsoNormal style='line-height:150%'>     (c)   the patient holds a
current, valid prescription for a benzodiazepine drug that is a Schedule III or
Schedule IV controlled dangerous substance.</p>

<p class=MsoNormal style='line-height:150%'>     (2)    A practitioner shall
not be required to issue more than one prescription for an opioid antidote to a
patient under paragraph (1) of this subsection per year. </p>

<p class=MsoNormal style='line-height:150%'>     (3)    Nothing in paragraph
(2) of this subsection shall be construed to prohibit a practitioner from
issuing additional prescriptions for an opioid antidote to a patient upon the
patient's request or when the practitioner determines there is a clinical or
practical need for the additional prescription.</p>

<p class=MsoNormal style='line-height:150%'>(cf: P.L.2021, c.54, s.1)</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     2.    Section 1 of P.L.1997,
c.249 (C.45:9-22.19) is amended to read as follows:</p>

<p class=MsoNormal style='line-height:150%'>     1. a. <b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>Except in the
case of an initial prescription issued pursuant to<b><span style='font-family:
"Albertus Extra Bold",sans-serif'>]</span></b> <u>Subject to the limitations
set forth in</u> section 11 of P.L.2017, c.28 (C.24:21-15.2), a physician
licensed pursuant to chapter 9 of Title 45 of the Revised Statutes may
prescribe a Schedule II controlled dangerous substance for the use of a patient
in any quantity which does not exceed a 30-day supply, as defined by
regulations adopted by the State Board of Medical Examiners in consultation
with the Department of Health. The physician shall document the diagnosis and
the medical need for the prescription in the patient's medical record, in accordance
with guidelines established by the State Board of Medical Examiners.</p>

<p class=MsoNormal style='line-height:150%'>     b.    <b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>Except in the
case of an initial prescription issued pursuant to<b><span style='font-family:
"Albertus Extra Bold",sans-serif'>]</span></b> <u>Subject to the limitations
set forth in</u> section 11 of P.L.2017, c.28 (C.24:21-15.2), a physician may
issue multiple prescriptions authorizing the patient to receive a total of up
to a 90-day supply of a Schedule II controlled dangerous substance, provided
that the following conditions are met:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   each separate
prescription is issued for a legitimate medical purpose by the physician acting
in the usual course of professional practice;</p>

<p class=MsoNormal style='line-height:150%'>     (2)   the physician provides
written instructions on each prescription, other than the first prescription if
it is to be filled immediately, indicating the earliest date on which a pharmacy
may fill each prescription;</p>

<p class=MsoNormal style='line-height:150%'>     (3)   the physician determines
that providing the patient with multiple prescriptions in this manner does not
create an undue risk of diversion or abuse; and</p>

<p class=MsoNormal style='line-height:150%'>     (4)   the physician complies
with all other applicable State and federal laws and regulations.</p>

<p class=MsoNormal style='line-height:150%'>(cf: P.L.2017, c.28, s.12)</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     3.    This act shall take
effect immediately.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:150%'>STATEMENT</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     This bill provides certain
limits on the amount of opioid medication that may be prescribed to a patient. 
</p>

<p class=MsoNormal style='line-height:150%'>     Under the bill, whenever a health
care practitioner or physician prescribes an opioid medication to a patient,
the health care practitioner or physician is to be prohibited from prescribing
more than a seven-day supply of the medication.  However, if a health care
practitioner or physician determines, in his or her professional judgment, that
the prescription of more than a seven-day supply of opioid medication is
necessary to treat a patients acute medical condition, or is necessary to
provide the patient with adequate management of chronic pain, the practitioner
may issue a prescription of more than a seven-day supply of opioid medication. 
The quantity of opioid medication prescribed under this bill is not to exceed
the amounts specified in section 1 of P.L.1997, c.249 (C.45:9-22.19), and is to
be consistent with any other applicable State and federal prescribing
requirements.</p>

</div>

</body>

</html>
